Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia.
The basal ganglia have received increasing attention with regard to their role in time pacing, motor function and other components of cognition. The aim of this study was to test whether the finer the motor activity and/or time perception performance were, the higher the striatal dopamine D(2) binding would be. Single photon emission computed tomography (SPECT) with [(123)I]iodobenzamide (IBZM) was performed to measure striatal D(2) receptor densities. A battery of neuropsychological tests, including the Wisconsin Card Sorting Test (WCST), the finger tapping test (FTT), and an attention test, was performed by patients with schizophrenia. Results indicated a strong correlation between the FTT score and striatal D(2) receptor binding. Neuroleptic dosage plays an important role in the relationship between cognitive tasks and striatal dopamine receptor densities. In addition, the striatal D(2) receptor density is more significantly correlated with attentional tests that consider the time effect than those that do not. Among the three tests performed, the WCST was least significantly correlated with striatal D(2) receptor densities. A decrease in striatal dopamine D(2) receptor density seems to be associated with impaired performance on optimal timing tasks and motor processing in patients with schizophrenia.
Yang
Yen Kuang
YK
Department of Psychiatry, College of Medicine, National Cheng Kung University and University Hospital, 138 Sheng Li Road, Tainan 70428, Taiwan. ykyang@mail.edu.tw
Yeh
Tzung Lieh
TL
Chiu
Nan Tsing
NT
Lee
I Hui
IH
Chen
Po See
PS
Lee
Li-Ching
LC
Jeffries
Keith J
KJ
D000328:Adult; D001288:Attention / Q000187:drug effects / Q000502:physiology; D001549:Benzamides; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D004193:Discrimination Learning / Q000187:drug effects / Q000502:physiology; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009483:Neuropsychological Tests; D010364:Pattern Recognition, Visual / Q000187:drug effects / Q000502:physiology; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D012565:Schizophrenic Psychology; D013223:Statistics as Topic; D013998:Time Perception / Q000187:drug effects / Q000502:physiology*; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D004298:Dopamine